We measured adult heights of 95 healthy GH sufficient children (peak GH> 10 ng/ml, polyclonal RIA) whose heights at presentation were more than 2 standard deviations (SD) below the mean for chronological age (CA), normal weight to height ratios, normal body proportions, and pathologic growth velocity for CA. Group 1 (N=32, 4 females) received standardized doses (0.3 mg/kg/week) of growth hormone (mean duration = 40 months, range 16 to 66 months), while group 2 (N=63, 17 females) received no treatment. Baseline data and height outcomes as follows (mean): Conclusion: Final height SDS in the GH treated group was significantly greater than in the untreated group, p<.001. Target height was met or exceeded by 44% of the GH treated group but only 13% of the untreated group. Predicted height was met or exceeded by 67% of the GH treated group in contrast to 43% for the untreated group. We conclude that GH treatment provided better height outcomes for the majority of children with idiopathic growth failure. Table

Table 1
Full size table